Upon its 'reinvention', thalidomide was quickly applied to 'microenvironment-dependent' diseases such as multiple myeloma, yet its role in the solid tumor spectrum has not been validated.

Thalidomide, a sedative that caused severe birth defects 50 years ago when it was prescribed to pregnant women, has enjoyed revived interest owing to its potency as an antiangiogenic and anti ...